The main objective of the present study was to examine the role of motivation and action orientation in forming spontaneous (i.e., without specific instruction or manipulation) implementation ...intentions for a healthy diet goal. We hypothesized that (1) the adoption of a diet goal would be determined by (either intrinsic or extrinsic) motivation only whereas, (2) forming implementation intentions would be determined by intrinsic motivation and (either low or high) action orientation. These hypotheses were addressed in a sample of 142 normal weight subjects who were concerned about their dietary habits. Primary outcomes were goal intentions and implementation intentions. Our hypothesis regarding the prediction of goal intentions was confirmed whereas results relating to the prediction of implementation intentions demonstrated that intrinsic motivation and low (but not high) action orientation proved significant predictors of intentions to implement a healthy diet goal. These findings suggest that self-regulatory skills as assessed by the concept of action orientation may relate to short-term strategies of initiating behavior change only. PUBLICATION ABSTRACT
In our paper 'Obesity, overconsumption and self-regulation failure: The unsung role of eating appropriateness standards', we argued that it is not the omnipresent availability of palatable foods ...alone - what is generally called the 'obesogenic environment' - that should be held responsible for the epidemic of overweight, but also the absence of norms of appropriateness about what, where and when to eat, that goes hand in hand with this abundant presence of foods. Siegfried Dewitte and Peter Herman and Janet Polivy shared their thoughts about this proposition and we appreciate the opportunity to discuss this issue more elaborately.
Gut immaturity is linked with postnatal intestinal disorders. However, biomarkers to assess the intestinal developmental stage around birth are lacking. The aim of this study was to gain more insight ...on intestinal fatty acid-binding protein (I-FABP) as an indicator of gut maturity.
Antenatal I-FABP distribution and release was investigated in extremely premature, moderately premature, and term lambs, and these findings were verified in human urinary samples. Ileal I-FABP distribution was confirmed in autopsy material within 24 h postnatally.
Median (range) serum I-FABP levels were lower in extremely premature lambs compared with moderately premature lambs (156 (50.0-427) vs. 385 (100-1,387) pg/ml; P = 0.02). Contrarily, median early postnatal urine I-FABP levels in human infants were higher in extremely premature compared with moderately premature and term neonates (1,219 (203-15,044) vs. 256 (50-1,453) and 328 (96-1,749) pg/ml; P = 0.008 and P = 0.04, respectively). I-FABP expression was most prominent in nonvacuolated enterocytes and increased with rising gestational age (GA) in ovine and human tissue samples. The epithelial distribution pattern changed from a phenotype displaying I-FABP-positive enterocytes merely in the crypts early in gestation into a phenotype with I-FABP expressing cells exclusively present in the villus tips at term in ovine and human tissue.
In this ovine and human study, increasing GA is accompanied by an increase in I-FABP tissue content. Cord I-FABP levels correlate with gestation in ovine fetuses, identifying I-FABP as a marker for gut maturation. Raised postnatal urine I-FABP levels in preterm human infants may indicate intestinal injury and/or inflammation in utero.
Surgery for pelvic organ prolapse (POP) is associated with high recurrence rates. The costs associated with the treatment of recurrent POP are huge, and the burden from women who encounter recurrent ...POP, negatively impacts their quality of life. Estrogen therapy might improve surgical outcome for POP due to its potential beneficial effects. It is thought that vaginal estrogen therapy improves healing and long-term maintenance of connective tissue integrity. Hence, this study aims to evaluate the cost-effectiveness of perioperative vaginal estrogen therapy in postmenopausal women undergoing POP surgery.
The EVA trial is a multi-center double-blind randomized placebo-controlled trial conducted in the Netherlands comparing the effectiveness and costs-effectiveness of vaginal estrogen therapy. This will be studied in 300 postmenopausal women undergoing primary POP surgery, with a POP-Q stage of ≥ 2. After randomization, participants administer vaginal estrogen cream or placebo cream from 4 to 6 weeks preoperative until 12 months postoperative. The primary outcome is subjective improvement of POP symptoms at 1 year follow-up, measured with the Patient Global Impression of Improvement (PGI-I) scale. Secondary outcomes are POP-Q anatomy in all compartments, re-interventions, surgery related complications, general and disease specific quality of life, sexual function, signs and complaints of vaginal atrophy, vaginal pH, adverse events, costs, and adherence to treatment. Follow up is scheduled at 6 weeks, 6 months and 12 months postoperative. Data will be collected using validated questionnaires and out-patient visits including gynecological examination performed by an independent gynecologist.
This study investigates whether perioperative vaginal estrogen will be cost-effective in the surgical treatment of POP in postmenopausal women. It is hypothesized that estrogen therapy will show a reduction in recurrent POP symptoms and a reduction in reoperations for POP, with subsequent improved quality of life among women and cost savings. Trial registrationNetherlands Trial Registry: NL6853; registered 19-02-2018, https://www.trialregister.nl/trial/6853 . EudraCT: 2017-003144-21; registered: 24-07-2017.
PDF
